These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28741476)

  • 1. Squamous Transition of Lung Adenocarcinoma and Drug Resistance.
    Hou S; Han X; Ji H
    Trends Cancer; 2016 Sep; 2(9):463-466. PubMed ID: 28741476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
    J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.
    Park S; Han J; Sun JM
    Lung Cancer; 2019 Jan; 127():66-68. PubMed ID: 30642554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.
    Hou S; Zhou S; Qin Z; Yang L; Han X; Yao S; Ji H
    Am J Pathol; 2017 May; 187(5):954-962. PubMed ID: 28284717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
    J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
    Jukna A; Montanari G; Mengoli MC; Cavazza A; Covi M; Barbieri F; Bertolini F; Rossi G
    J Thorac Oncol; 2016 Apr; 11(4):e49-51. PubMed ID: 26746366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
    Moldvay J; Peták I
    Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors.
    Dohzono S; Sasaoka R; Takamatsu K; Nakamura H
    Int J Clin Oncol; 2017 Aug; 22(4):698-705. PubMed ID: 28361340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.
    Wang Z; Shen Z; Li Z; Duan J; Fu S; Liu Z; Bai H; Zhang Z; Zhao J; Wang X; Wang J
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9990-5. PubMed ID: 26216950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
    Grosse A; Grosse C
    Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
    [No Abstract]   [Full Text] [Related]  

  • 17. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells.
    Wang S; Takayama K; Tanaka K; Takeshita M; Nakagaki N; Ijichi K; Li H; Nakanishi Y
    J Thorac Oncol; 2013 Jun; 8(6):719-25. PubMed ID: 23625155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW; Wu TC; Chen CY; Lee H
    Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
    Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
    Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.